Stock comparison
Genmab A/S
Smith & Nephew
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
SNN
Smith & Nephew
Market cap
$13.01B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | SNN | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 54C | GMAB |
| Benjamin Graham | 64C | 68B | SNN |
| Philip Fisher | 48D | 45D | GMAB |
| Peter Lynch | 25F | 57C | SNN |
| Joel Greenblatt | 76B | 33F | GMAB |
| Charlie Munger | 68C | 47D | GMAB |
| Terry Smith | 71C | 49D | GMAB |
Side-by-side metrics
| Metric | GMAB | SNN |
|---|---|---|
| Market cap | $16.5B | $13.01B |
| P/E (TTM) | 6.2x | 20.3x |
| EV/EBIT | 12.0x | 15.5x |
| ROIC (TTM) | 43.78% | 9.11% |
| Gross margin | 93.88% | 68.01% |
| Net margin | 18.23% | 10.14% |
| Revenue CAGR 5y | -18.45% | 4.34% |
| EPS CAGR 5y | -23.48% | 5.03% |
| Debt / Equity | 0.1x | 0.6x |
| Dividend yield | 0.0% | 2.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 0.6x+88%
- ROIC (TTM)43.78%vs 9.11%+79%
- P/E (TTM)6.2xvs 20.3x+70%
- Net margin18.23%vs 10.14%+44%
SNN leads on
- Revenue CAGR 5y4.34%vs -18.45%+124%
- EPS CAGR 5y5.03%vs -23.48%+121%
- Dividend yield2.62%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.